PT Kalbe Farma Tbk (KLBF) has received approval from the Food and Drug Supervisory Agency BPOM to conduct a Phase 2b/3 clinical trial for the COVID-19 GX-19N vaccine in Indonesia.

The implementation of clinical trials from phase 2b/3 will start in July 2021 and is expected to carry out an interim analysis for safety and efficacy (the ability of the vaccine to induce immunity to COVID-19) by the end of 2021.

"Kalbe is grateful to the POM and the ethics committee for granting permission to conduct a clinical trial of the COVID-19 GX-19N vaccine. Currently, the need for a COVID-19 vaccine in Indonesia is still not sufficient. As an innovation-based health company, we hope that what Kalbe has made a contribution to the prevention of COVID-19 in Indonesia," said Kalbe President Commissioner Irawati Setiady in a statement on Monday (12/7).

According to Irawati, if the clinical trial phase 2b/3 is considered successful and gets approval for emergency